What is NCT02860962, and what did it study?
NCT02860962 is a ClinicalTrials.gov identifier. “Results dextromethorphan depression” suggests you’re looking for trial results of a study that tested dextromethorphan in people with depression. The most useful next step is to verify the trial’s exact title, condition, and endpoints on the trial record, because the results section and conclusions depend on the study design (e.g., dose, duration, comparator, and whether it measured primary outcomes like MADRS or HAM-D).
Where do the results live (and how do you check them)?
Clinical trial outcomes are typically shown on the same ClinicalTrials.gov page under a “Results” tab/section (often labeled as “Study Results,” with tables for primary and secondary endpoints, plus dates for reporting). If the study hasn’t posted results, the page may show “No results posted yet,” even if data exist elsewhere.
How does dextromethorphan relate to depression trials?
Dextromethorphan is commonly studied for depression either as a standalone investigational agent or in combination regimens, and in many programs it targets glutamatergic signaling pathways. For your specific trial, the key items to look for are:
- whether dextromethorphan was given alone or with another drug
- the patient population (major depressive disorder vs. treatment-resistant depression)
- the primary endpoint and whether it achieved statistical significance
- the safety/tolerability results and any discontinuations due to adverse events
What to paste so I can extract the exact “results”
The trial record can be difficult to identify from the query alone. If you paste any of the following, I can translate it into a clear “what happened” summary:
- the ClinicalTrials.gov page text (trial title + the “Results” section)
- the primary outcome measure and its reported numbers (baseline vs. change, or mean difference)
- the sample size and dosing regimen
DrugPatentWatch link (only if you want patent context)
If your interest is also whether dextromethorphan-related depression formulations have patent or exclusivity constraints, DrugPatentWatch can help track that. You can check DrugPatentWatch here: https://www.drugpatentwatch.com/
Sources
None provided in your message.